AU3725697A - Infectious papillomavirus pseudoviral particles - Google Patents

Infectious papillomavirus pseudoviral particles

Info

Publication number
AU3725697A
AU3725697A AU37256/97A AU3725697A AU3725697A AU 3725697 A AU3725697 A AU 3725697A AU 37256/97 A AU37256/97 A AU 37256/97A AU 3725697 A AU3725697 A AU 3725697A AU 3725697 A AU3725697 A AU 3725697A
Authority
AU
Australia
Prior art keywords
gene
biological species
papillomavirus
derived
pseudoviral particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU37256/97A
Other versions
AU732125B2 (en
Inventor
Douglas R Lowy
Richard B. Roden
John T Schiller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU3725697A publication Critical patent/AU3725697A/en
Application granted granted Critical
Publication of AU732125B2 publication Critical patent/AU732125B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides an infectious papillomavirus pseudoviral particle useful in gene transfer comprising: (a) a papillomavirus vector DNA which comprises an E2 binding site and an expression cassette comprising a gene and a sequence controlling expression of said gene; and (b) a papillomavirus capsid which comprises L1 and L2 structural proteins, such that said capsid encapsidates said vector DNA, wherein said gene is derived from a first biological species and said L1 structural protein is derived from a second biological species and said first biological species is different from said second biological species.
AU37256/97A 1996-07-17 1997-07-14 Infectious papillomavirus pseudoviral particles Expired AU732125B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2210496P 1996-07-17 1996-07-17
US60/022104 1996-07-17
PCT/US1997/012115 WO1998002548A2 (en) 1996-07-17 1997-07-14 Infectious papillomavirus pseudoviral particles

Publications (2)

Publication Number Publication Date
AU3725697A true AU3725697A (en) 1998-02-09
AU732125B2 AU732125B2 (en) 2001-04-12

Family

ID=21807834

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37256/97A Expired AU732125B2 (en) 1996-07-17 1997-07-14 Infectious papillomavirus pseudoviral particles

Country Status (8)

Country Link
US (2) US6599739B1 (en)
EP (1) EP0922105B1 (en)
JP (1) JP2000515741A (en)
AT (1) ATE312178T1 (en)
AU (1) AU732125B2 (en)
CA (1) CA2257822A1 (en)
DE (1) DE69734829D1 (en)
WO (1) WO1998002548A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
JP2003504014A (en) * 1999-06-30 2003-02-04 エボテック オーアーイー アクチェンゲゼルシャフト Viral particles, their preparation and preferably their use in pharmaceutical screening and functional genomes
GB0007231D0 (en) 2000-03-24 2000-05-17 Chiron Spa Modified rna for gene delivery
CA2415763A1 (en) * 2000-07-07 2002-01-17 Merck & Co., Inc. Production of chimeric human papillomavirus
FI116851B (en) 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Expression vector, its uses and process for its preparation and products containing it
CN1114690C (en) * 2001-05-15 2003-07-16 乔良 Papilloma pseudovirus and process for preparing same
US7247433B2 (en) 2001-08-13 2007-07-24 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
ITVA20050021A1 (en) 2005-04-01 2006-10-02 Sergio Biucchi OFF-LINE COMPUTER DEVICES FOR THE SYSTEM OF SELF-MANAGED CURRENCY TRANSACTIONS
WO2007064971A2 (en) * 2005-12-01 2007-06-07 The Government Of The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Infectious papovavirus particle comprising a cytocidal gene and methods of use thereof
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
ES2653251T3 (en) * 2009-04-10 2018-02-06 The Johns Hopkins University Particles of the papillomavirus (VLP) type as broad-spectrum human papillomavirus (HPV) vaccines
US9724404B2 (en) * 2009-04-13 2017-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) HPV particles and uses thereof
WO2011017162A2 (en) * 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
EA201592264A1 (en) * 2009-08-26 2016-08-31 Селекта Байосайенсиз, Инк. COMPOSITIONS WHICH INDUCE T-CELL HELPER EFFECT
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
WO2015042325A1 (en) 2013-09-18 2015-03-26 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
MA43134A (en) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc COMPOSITIONS AND METHODS OF TUMOR TRANSDUCTION
CA3002674A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
CN108473950A (en) 2015-10-30 2018-08-31 美国政府卫生与公众服务部 Targeted cancer therapy
DE102016215500B4 (en) * 2016-08-18 2020-02-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Sensor system for characterizing the state of samples of a heterogeneous biomass structure contained in a culture vessel
US20200330582A1 (en) 2017-11-06 2020-10-22 The Usa, As Represented By The Secretary, Department Of Health And Human Services Cancer treatment utilizing pre-existing microbial immunity
CN116350803B (en) * 2023-05-19 2023-11-24 健通(济南)生物科技有限公司 mRNA drug delivery system taking papillomavirus-like particles as carrier and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5792931A (en) * 1994-08-12 1998-08-11 Pioneer Hi-Bred International, Inc. Fumonisin detoxification compositions and methods
PT809700E (en) 1994-10-07 2006-09-29 Univ Loyola Chicago PARTICLES SIMILAR TO PAPILLOMAVIRUS AND FUSEOUS PROTEINS, AND METHODS FOR THEIR PRODUCTION
FR2749323B1 (en) 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc PSEUDO-PARTICLES VIRALES USEFUL AS A VECTOR OF NUCLEIC ACID DELIVERY
DK1015561T3 (en) * 1997-09-05 2006-11-13 Medimmune Inc In vitro method for separation / re-assembly of papillomavirus-like particles (VLPs)

Also Published As

Publication number Publication date
WO1998002548A2 (en) 1998-01-22
CA2257822A1 (en) 1998-01-22
ATE312178T1 (en) 2005-12-15
DE69734829D1 (en) 2006-01-12
EP0922105B1 (en) 2005-12-07
JP2000515741A (en) 2000-11-28
EP0922105A2 (en) 1999-06-16
AU732125B2 (en) 2001-04-12
US6599739B1 (en) 2003-07-29
WO1998002548A3 (en) 1998-03-05
US20030207446A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
AU3725697A (en) Infectious papillomavirus pseudoviral particles
AU7025100A (en) Selection system
CA2383926A1 (en) Functional genomics using zinc finger proteins
AU681705B2 (en) Endosomolytically active particles
GB2325003B (en) Rectroviral vectors
AU7335296A (en) Recombinant sendai virus
IL118259A0 (en) Recombinant viral vector system
WO2002099035A3 (en) Chimeric alphavirus replicon particles
WO1998049286A3 (en) Directed evolution of enzymes and antibodies
AUPN477695A0 (en) Gene therapy
AU2002235884A1 (en) Method for the identification of extracellular domains of the epstein barr virus (ebv), tumor-associated latent membrane proteins and for the selection of antibody reagents reactive therewith
AU1686395A (en) (deltex) proteins, nucleic acids, and antibodies, and related methods and compositions
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
AU7567994A (en) Tumor suppressor protein prb2, related gene products, and dna encoding therefor
WO2002096939A3 (en) Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
WO2001044809A3 (en) Evaluation of biological agents in living target cells
AU1727597A (en) Purified sr-p70 protein
AU4952097A (en) Anti-p53 single-chain antibody fragments and their uses
ES2132025A1 (en) Plant grab proteins
AU8405798A (en) A swine hepatitis e virus and uses thereof
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
EP1521839B8 (en) Methods of making viral particles having a modified cell binding activity and uses thereof
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
EP2385124A3 (en) Peptides or peptide analogues for modulating the binding of a PDZ protein and a PL protein
AUPO816297A0 (en) Nucleic acid molecules specific for bacterial antigens and uses thereof (II)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)